"Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control."@en . "* 28.3 L"@en . . "AC002993"@en . . "AC2993"@en . "141758-74-9"@en . "Exenatide synthetic"@en . " "@en . "Matthieu Giraud, Anne-Sophie Droz, Stephane Varray, El Djouhar Rekai, Marie-Helene Brichard, Daniel Latassa, Christine Devijver, Pascal Gilles, Jeanne-Marie Cauvin, Fernando Albericio, Marta Paradis Bas, \"PROCESS FOR THE PRODUCTION OF EXENATIDE AND OF AN EXENATIDE ANALOGUE.\" U.S. Patent US20110046349, issued February 24, 2011."@en . . . . . "Effects of the overdoses included severe nausea, severe vomiting, and rapidly declining blood glucose concentrations."@en . "AC 2993"@en . "# Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 Oct 18;143(8):559-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16230722"@en . . . "approved"@en . "Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2.1 hours."@en . . "Exenatide, derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, is a functional analog of Glucagon-Like Peptide-1 (GLP-1), a naturally occuring peptide."@en . . "Mean terminal half-life is 2.4 hours."@en . "Humans and other mammals"@en . . . . . "AC2993a"@en . "Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). Incretins enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoiding inappropriately high insulin levels during fasting. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia. Secondary effects of drug administration reduces the rate of gastric emptying and decreases food intake, mitigating the potential severity of hyperglycemic events after meals."@en . . "Bydureon"@en . . . . "* Apparent cl=9.1 L/hr"@en . . "Byetta"@en . "Exenatide"@en . . "Synthetic exendin-4"@en . . . "Exenatide"@en . . "AC-2993"@en . . . "investigational"@en . . . . "Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation."@en .